New Once-Daily Pill for Adults With HIV on Complex Treatment

Bixlenvo (bictegravir and lenacapavir) is a once-daily oral complete regimen. On the US Prescribing Information (revised 08/2026) it is indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen with no known or suspected resistance to the individual components of BIXLENVO.

This is a traditional FDA approval (NDA 221104). It is not listed on FDA’s 2026 Novel Drug Approvals table because bictegravir and lenacapavir were already marketed in other products; the new approved pathway is this fixed-dose combination for suppressed adults.

Distinct path — not this label: Idvynso (doravirine / islatravir) is a separate labelled tenofovir-free switch already covered elsewhere on Medcelerator. Biktarvy (bictegravir / emtricitabine / tenofovir alafenamide) is a three-drug STR — not this two-drug tablet. Sunlenca (lenacapavir) alone remains a separate product used here only for the two-day initiation load. Today’s US labelled once-daily bictegravir + lenacapavir complete-regimen switch for suppressed adults is Gilead Bixlenvo (NDA 221104).

The FDA approved NDA 221104 effective 27 August 2026. Applicant attention on the letter: April Raj, MS, Gilead Sciences, Inc., Foster City, CA. Letter signed Prabha Viswanathan, Division of Antivirals. Package Insert Reference ID 5859873. Manufactured for and distributed by Gilead Sciences, Inc., Foster City, CA 94404. Document code on patient labeling: 221104-GS-000.

Where this is taking place

Approved prescription route today: United States — FDA-labelled Bixlenvo for adults with HIV-1 who are already suppressed on a stable regimen, prescribed through an HIV / infectious-disease clinic (or another clinician managing HIV), with a two-day oral Sunlenca initiation then daily Bixlenvo maintenance. Company patient materials describe Gilead Advancing Access® for cost-support navigation and point to www.BIXLENVO.com. This is a prescription HIV antiretroviral conversation — not a cure, not PrEP, and not a DIY import.

Outside the United States: At the time of writing, no confirmed Health Canada Notice of Compliance, European Commission marketing authorisation, MHRA licence, TGA listing, Swissmedic authorisation, or PMDA/MHLW licence for Bixlenvo. Gilead’s August 2026 approval materials state bictegravir and lenacapavir in combination are not approved by any regulatory authority outside of the United States. Do not import on your own.

ARTISTRY-1 — NCT05502341 (GS-US-621-6289) — Randomized, open-label, multicenter Phase 3 switch from a complex stable baseline regimen to Bixlenvo vs staying on baseline. Lead sponsor: Gilead Sciences. CT.gov status at the time of writing: active but no longer taking new patients. Actual enrolment 689. USPI safety/efficacy N=557 randomized who received study drug in section 14 (Bixlenvo 371 / stay 186). Expanded access on this record: CT.gov reports expanded access: none listed.

ARTISTRY-2 — NCT06333808 (GS-US-621-6290) — Randomized, double-blind Phase 3 switch from Biktarvy to Bixlenvo vs staying on Biktarvy. Lead sponsor: Gilead Sciences. CT.gov status: active but no longer taking new patients. Actual enrolment 577. USPI N=574 (Bixlenvo 383 / Biktarvy 191). Expanded access: none listed.

Week 48 primary analyses support the label. That is not open new enrolment into the pivotal cohorts. It is also not the same as “any pharmacy will have Bixlenvo tomorrow without an HIV clinician.”

The practical prescription route in the US is an HIV clinician who can confirm suppression, review resistance history (no known/suspected BIC or LEN resistance), plan the two-day Sunlenca + Bixlenvo initiation, check drug interactions (including dofetilide and strong CYP3A inducers), and arrange Advancing Access / payer logistics if needed.

Approval matrix

Access by country

• United States: Ask an HIV / infectious-disease clinician about FDA-labelled Bixlenvo. Labelled 27 August 2026 as a complete regimen to replace current ART in adults already suppressed (RNA <50) on a stable regimen with no known or suspected resistance to bictegravir or lenacapavir. Path: confirm eligibility → Days 1 and 2: one Bixlenvo 75/50 mg tablet plus Sunlenca 600 mg (two 300 mg tablets) each day → Day 3 onward: one Bixlenvo tablet once daily → with or without food. If more than 7 days elapse since the last maintenance dose, restart the initiation regimen from Day 1 when continuing treatment is still clinically appropriate. Do not take Day 1 and Day 2 Sunlenca doses on the same day if a day was missed. Bottle: NDC 61958-3601-1 (30 tablets). Suspected adverse reactions: Gilead 1-800-GILEAD-5 or FDA MedWatch 1-800-FDA-1088. Patient information: 1-800-445-3235 or www.BIXLENVO.com. Cost-support navigation: Gilead Advancing Access® — 1-800-226-2056 (Mon–Fri 9 AM–8 PM ET on company materials) or gileadadvancingaccess.com. No list price or copay dollars in this article. This is US labelled commercial supply, not a DIY import.

• Canada: Bixlenvo authorisation not confirmed. Ask the Canadian HIV clinic what legal paths exist in Canada when a Canadian Bixlenvo label does not yet exist.

• European Union / United Kingdom / Australia / Japan / other countries: Regulator authorisation not confirmed on the sources checked. US trial sites are not a commercial foreign label. Do not import on your own.

• If your regulator has not authorised it: do not import on your own. Ask the local clinician about documented special-access / named-patient rules, referral to a centre in a labelled country, or waiting — without treating a US bottle as a foreign pack.

Who is eligible (from the US label)

This is an adult switch for people already undetectable on the Prescribing Information — not a first-start regimen and not a labelled rescue for people whose current ART is failing.

United States (USPI, revised August 2026):

• Indication: Complete regimen to replace current ART in adults with HIV-1 who are virologically suppressed (RNA <50 copies/mL) on a stable regimen with no known or suspected resistance to bictegravir or lenacapavir.
• Recommended dosage: Two-day initiation (Bixlenvo + oral Sunlenca 600 mg daily) then Bixlenvo once daily; with or without food.
• Contraindications: Concomitant dofetilide; strong CYP3A inducers.
• Warnings: Risk of adverse reactions or loss of virologic response from drug interactions — review full interaction table before and during therapy.
• Most common adverse reactions (≥2%, all grades, ARTISTRY): headache (4% ARTISTRY-1), nausea (3%), diarrhea (2%).
• Other ART: Because Bixlenvo is a complete regimen, coadministration with other antiretrovirals for HIV-1 treatment is not recommended.
• Pregnancy / lactation: Lower bictegravir exposures observed with a BIC-containing regimen in pregnancy — monitor viral load closely; Antiretroviral Pregnancy Registry 1-800-258-4263. Individuals with HIV-1 should be informed of potential risks of breastfeeding.
• Pediatrics: Safety and effectiveness not established.
• HBV co-infection: Chronic HBV was excluded from ARTISTRY; discuss HBV status with the clinician (section 8.8 on USPI).

ARTISTRY trial context (USPI): Both trials required suppression for ≥6 months before entry. ARTISTRY-1 complex baseline: mean 3.5 oral pills/day (range 2–11); 71% on INSTI + PI–containing regimens among those described. ARTISTRY-1 mean age 59 (range 22–84); ARTISTRY-2 mean age 49 (range 23–77).

Not labelled on the sources checked for this article:

• Adults starting ART for the first time (treatment-naïve).
• People with known/suspected resistance to bictegravir or lenacapavir, or whose current regimen is failing.
• Children and adolescents.
• Canadian, EU, UK, Japanese, Australian, or Swiss Bixlenvo marketing authorisations (not confirmed here).
• Treating NCT05502341 / NCT06333808 follow-up as open commercial enrolment.

What the pivotal studies showed (Prescribing Information)

Use the Prescribing Information for a prescription conversation. Journals are supportive reading.

ARTISTRY-1 and ARTISTRY-2 — Week 48 virologic outcomes (USPI Table 11):

Both CT.gov records were active but no longer taking new patients at the time of writing. A labelled commercial switch is not open pivotal enrolment.

How it is taken (US label)

Who / research team (primary sources only)

• Sponsor / applicant: Gilead Sciences, Inc., Foster City, CA (NDA letter; USPI).
• Letter attention: April Raj, MS, Associate Director, Regulatory Affairs (NDA 221104 approval letter).
• Pivotal trials: ARTISTRY-1 (NCT05502341); ARTISTRY-2 (NCT06333808) — lead sponsor Gilead Sciences on CT.gov.
• Patient support (company): Gilead Advancing Access® — 1-800-226-2056 / gileadadvancingaccess.com on company cost-support materials; product info 1-800-445-3235 / www.BIXLENVO.com on USPI patient labeling.
• Names and phones below are limited to what appears on the Prescribing Information, FDA approval letter, ClinicalTrials.gov, and clearly labelled company support materials.

Sources

1. FDA — NDA 221104 Approval Letter for Bixlenvo (bictegravir and lenacapavir) tablets (27 Aug 2026; Reference ID 5859873).
2. FDA / Gilead — Bixlenvo Prescribing Information (revised 08/2026).
3. Gilead Sciences — U.S. FDA Approves Gilead’s Bixlenvo… press release (27 Aug 2026).
4. ClinicalTrials.gov — NCT05502341 (ARTISTRY-1); NCT06333808 (ARTISTRY-2).
5. Company patient materials — www.BIXLENVO.com / Cost Support / Advancing Access (1-800-226-2056).

Not medical advice. Talk with a clinician who knows the full history before any treatment decision. Authorized is not funded.